Two Sigma Securities’s Royalty Pharma RPRX Stock Holding History

Two Sigma Securities’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,933	Closed	-$250K	–	3264
2023 Q1	$250K	Buy	+6,933	New	+$257K	0.01%	1884

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Securities's RPRX Position: Q2 2023 in Review

Two Sigma Securities sold out of Royalty Pharma (RPRX) in Q2 2023, closing a stake of 6,933 shares — an estimated $250K sold.

Two Sigma Securities first reported a position in RPRX in Q1 2023 and held it in 1 quarter. The position peaked at $250K in Q1 2023. 325 funds tracked by Wall St. Rank hold RPRX as of Q2 2023.

Two Sigma Securities reported no remaining Royalty Pharma position as of Q2 2023 after selling out during the quarter.
Two Sigma Securities sold 6,933 Royalty Pharma shares in Q2 2023, an estimated $250K.
Two Sigma Securities first reported a position in Royalty Pharma in Q1 2023 and held it in 1 quarter.
Two Sigma Securities's Royalty Pharma position peaked at $250K in Q1 2023.
325 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2023.

Based on Two Sigma Securities's 13F filing for Q2 2023, filed 14 Aug 2023.